Search

Search Constraints

You searched for: Author/Creator Grund, Birgit

Search Results

1. Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV. (1st March 2023)

2. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. (June 2013)

3. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). (February 2022)

4. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Issue 5 (May 2022)

5. Health Utility Estimates and Their Application to HIV Prevention in the United States: Implications for Cost-Effectiveness Modeling and Future Research Needs. Issue 2 (July 2020)

7. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Issue 10324 (5th February 2022)

8. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. (26th June 2017)

9. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. (24th April 2017)

10. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy. (21st May 2013)